10-Q: Athira Pharma Reports Q2 2024 Results, Provides Update on Clinical Trials

Athira Pharma's Q2 2024 report details financial results and provides updates on clinical trials, including the upcoming topline results for the LIFT-AD trial.

Summary

• Athira Pharma, a late clinical-stage biopharmaceutical company, released its Q2 2024 financial results.
• The company reported a net loss of $53.2 million for the six months ended June 30, 2024, compared to a net loss of $57.4 million for the same period in 2023.
• Research and development expenses increased slightly to $43.4 million for the six months ended June 30, 2024, from $42.9 million in the prior year period.
• General and administrative expenses decreased to $12.3 million for the six months ended June 30, 2024, from $18.5 million in the prior year period.
• As of June 30, 2024, Athira had cash, cash equivalents, and investments totaling $91.8 million.
• The company estimates that its current cash, cash equivalents, and investments will be sufficient to fund operations for at least the next 12 months.
• Topline results for the LIFT-AD trial are expected by the end of the third quarter of 2024.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the company has made progress in reducing losses and has sufficient cash for the next 12 months, it still faces significant risks and challenges, including the need for additional funding and the uncertainty of clinical trial outcomes. The lack of revenue and continued losses are concerning.

Positives

• The company's net loss decreased compared to the same period last year.
• General and administrative expenses decreased significantly.
• The company has sufficient cash to fund operations for at least the next 12 months.
• The LIFT-AD trial has completed dosing and topline results are expected soon.

Negatives

• The company continues to incur significant losses.
• Research and development expenses remain high.
• The company has not generated any revenue from drug product sales.

Risks

• The company is a late clinical-stage biopharmaceutical company with a limited operating history.
• The company's ability to generate revenue and achieve profitability depends significantly on its ability to achieve a number of objectives.
• The company's development of fosgonimeton may never lead to a marketable product.
• The company's approach to targeting neurotrophic factors through the use of small molecules is based on a novel therapeutic approach, which exposes it to unforeseen risks.
• The company has limited data from its Phase 1a/1b and Phase 2 clinical trials to date, and it cannot be certain that future trials will yield data in support of the safety, efficacy and tolerability of its drug candidates.
• The company has concentrated its research and development efforts on the treatment of central and peripheral nervous system degenerative disorders, a field that has seen very limited success in product development.
• The company is and may in the future be subject to claims, lawsuits, arbitration proceedings, government investigations and other legal, regulatory and administrative proceedings and face potential liability and expenses related thereto, which could have a material adverse effect on its business, operating results and financial condition.
• Any topline, interim, initial, or preliminary data from the company's clinical trials that it announces or publishes from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.
• The company's reporting of topline or final data for its clinical trials may be delayed and its regulatory submissions or receipt of necessary marketing approvals could be delayed or prevented.
• Clinical development involves a lengthy and expensive process with an uncertain outcome, and results of early, smaller-scale preclinical studies and clinical trials with a single or few clinical trial sites may not be predictive of eventual safety or effectiveness in large-scale potentially pivotal clinical trials across multiple clinical trial sites.
• The company may encounter substantial delays in clinical trials, or may not be able to conduct or complete clinical trials on the expected timelines, if at all.
• The company's success depends on its ability to protect its intellectual property and its proprietary technologies.
• If the scope of any patent protection the company obtains is not sufficiently broad, or if it loses any of its patent protection, its ability to prevent its competitors from commercializing similar or identical product candidates would be adversely affected.
• The company faces significant competition, and if its competitors develop and market technologies or products more rapidly than it does or that are more effective, safer, or less expensive than the drug candidates it develops, its commercial opportunities will be negatively impacted.
• The company may expend its limited resources to pursue a particular drug candidate or indication and fail to capitalize on drug candidates or indications that may be more profitable or for which there is a greater likelihood of success.
• The loss of any of the company's key personnel could significantly harm its business, results of operations and competitive position.
• The company has incurred significant losses since its inception and anticipates that it will continue to incur significant losses for the foreseeable future.
• The company will require substantial additional funding to finance its operations, complete the development and commercialization of fosgonimeton, and develop and commercialize other and future drug candidates. If it is unable to raise this funding when needed, it may be forced to delay, reduce, or eliminate its drug product development programs or other operations.
• The regulatory approval processes of the U.S. Food and Drug Administration, or FDA, and other comparable foreign regulatory authorities are lengthy, time consuming and inherently unpredictable. If the company is not able to obtain, or if there are delays in obtaining, required regulatory approvals for its drug candidates, it will not be able to commercialize, or will be delayed in commercializing, its drug candidates, and its ability to generate revenue will be materially impaired.
• The company relies on third parties to conduct its nonclinical studies and clinical trials. If these third parties do not properly and successfully carry out their contractual duties or meet expected deadlines, it may not be able to obtain regulatory approval of or commercialize its drug candidates.
• Even if approved, the company's drug candidates may not achieve adequate market acceptance among physicians, patients, healthcare payors and others in the medical community necessary for commercial success.
• The company has never commercialized a drug candidate before and may lack the necessary expertise, personnel and resources to successfully commercialize any drug products on its own or together with suitable collaborators.
• Intellectual property discovered or developed through government funded programs may be subject to federal regulations such as march-in rights, certain reporting requirements and a manufacturing preference for U.S.-based companies. Compliance with such regulations may limit the company's exclusive rights and limit its ability to contract with non-U.S. manufacturers, which could adversely affect its ability to successfully develop and commercialize its drug products.
• The market price of the company's common stock has been and may continue to be volatile, which could result in substantial losses for investors.
• The company and certain of its directors and executive officers have been, and may in the future be, named as defendants in lawsuits that could result in substantial costs and divert managements attention.
• Actions by activist stockholders have in the past been, and may in the future be, disruptive and could cause uncertainty about the strategic direction of the company.

Future Outlook

The company estimates that its existing cash, cash equivalents and investments will be sufficient to fund its operating expenses and capital expenditure requirements through at least the next 12 months following the date of this report. Topline results for the LIFT-AD trial are expected by the end of the third quarter of 2024.

Management Comments

• Based upon the Company's current operating plan, it estimates that its $91.8 million of cash, cash equivalents and investments at June 30, 2024 will be sufficient to fund its operating expenses and capital expenditure requirements through at least the 12 months following the date of this report.

Industry Context

The company is operating in the competitive biopharmaceutical industry, specifically targeting neurodegenerative diseases, which has seen limited success in product development. The company's focus on small molecules and the neurotrophic HGF system represents a novel approach in this challenging field.

Comparison to Industry Standards

• The company's cash burn rate is typical for a clinical-stage biotech company, but it is important to note that the company has not yet generated any revenue from drug product sales.
• The company's R&D expenses are in line with other companies in the same stage of development, but the company's G&A expenses are lower than some of its peers.
• The company's reliance on third-party manufacturers is common in the industry, but it does introduce risks related to supply chain and quality control.
• The company's focus on Alzheimer's disease is in line with the industry's focus on addressing unmet medical needs in this area, but the company faces competition from other companies developing treatments for the same indication, such as Biogen and Eisai with lecanemab and Eli Lilly with donanemab.

Legal Proceedings

• The company is involved in securities class action lawsuits and shareholder derivative actions related to alleged false and misleading statements and breaches of fiduciary duty.
• The company has reached a settlement in principle in the securities class action, which is subject to court approval.
• The company has reached a settlement in the shareholder derivative action, which has been approved by the court.
• The company received a Civil Investigative Demand from the Department of Justice and is cooperating with the investigation.

Stakeholder Impact

• Shareholders face the risk of continued losses and potential dilution.
• Employees face the risk of job insecurity due to the company's financial situation.
• Patients may benefit from the development of new treatments for neurodegenerative diseases, but there is no guarantee of success.
• Suppliers and creditors face the risk of non-payment if the company's financial situation worsens.

Next Steps

• The company is targeting to report topline LIFT-AD results by the end of the third quarter of 2024.
• The company will continue to advance fosgonimeton and its other drug candidates through preclinical studies and clinical trials.
• The company will continue the open label extension of the ACT-AD and LIFT-AD trials.
• The company will continue to grow its discovery organization and invest in its drug development programs.
• The company will continue to ramp up manufacturing activities.
• The company will continue to attract, hire and retain additional personnel.
• The company will continue to obtain, maintain, expand and protect its intellectual property portfolio.
• The company will continue to operate as a public company.
• The company will continue to expand its laboratory and office facilities.
• The company will continue to implement and maintain operational, financial and management information systems.
• The company will seek regulatory approval for any drug candidates that successfully complete clinical trials.
• The company will establish a sales, marketing and distribution infrastructure to commercialize any drug candidate for which it may obtain marketing approval.
• The company will incur legal expenses associated with ongoing litigation.

Key Dates

Keywords

Athira Pharma, Fosgonimeton, Alzheimer's disease, Clinical trials, Neurodegenerative diseases, Biopharmaceutical, Drug development, LIFT-AD, ACT-AD, Financial results